HC Wainwright & Co. Reiterates Buy on Kezar Life Sciences, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Kezar Life Sciences (NASDAQ:KZR) and maintained a $20 price target.
March 15, 2024 | 10:43 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kezar Life Sciences receives a reiterated Buy rating and a $20 price target from HC Wainwright & Co.
The reiteration of a Buy rating and a maintained price target of $20 by a reputable analyst firm like HC Wainwright & Co. is a strong positive signal for Kezar Life Sciences. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100